Compare HCA Health Inc (HCA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Rocket Lab USA Inc — how do they compare? HCA Health Inc trades at $412.93 (market cap $89.08B), while Rocket Lab USA Inc trades at $80.86 (market cap $50.01B). The key difference: HCA Health Inc is the larger of the two by market cap, and HCA Health Inc pays a 0.76% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| HCA | RKLB | |
|---|---|---|
Market Cap | $89.08B | $50.01B |
Sector | Health | Technology |
52-Week High | $545.13 | $150.23 |
52-Week Low | $361.32 | $39.48 |
Enterprise Value | $139.62B | $47.84B |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $413.27, down 0.18% on the day, with strong technical momentum showing a bullish moving average signal. The company reported solid Q2 2026 earnings with EPS of $7.59 beating estimates of $7.56, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $75.60 billion, while maintaining healthy profit margins of 8.77%. Recent management appointments and ongoing legal investigations create mixed sentiment around the stock.
HCA presents a compelling value opportunity with attractive valuation multiples (P/E 13.8, EV/EBITDA 8.8) and strong analyst support (63% buy ratings, $449.93 price target). However, investors face risks from multiple ongoing legal investigations, high debt levels (debt-to-asset ratio 80.9% in 2025), and margin pressure from rising operational costs. The stock offers 8.9% upside to consensus target but requires monitoring of legal developments and expense management.
Rocket Lab (RKLB) trades at $81.06, up 1.27% today, with a bullish technical signal from moving averages and a record $2.36 billion backlog supporting growth. Revenue grew 60% year-over-year in Q2 2026, though net losses persist, and the stock is expensive with a P/S ratio of 60.8. Recent news highlights Neutron rocket development delays but strong contract wins.
The outlook is mixed: analyst consensus is bullish with a $118 price target, but profitability remains elusive until 2027. Key risks include execution on Neutron launches, high valuation, and cash burn. Upside depends on successful scaling and margin improvement from government contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
